These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 20652657

  • 21. [Post-transfusional iron overload, iron loading anemia].
    Rose C.
    Rev Med Interne; 2012 Jun; 33 Suppl 1():S15-8. PubMed ID: 22475955
    [No Abstract] [Full Text] [Related]

  • 22. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F.
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [Abstract] [Full Text] [Related]

  • 23. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E.
    Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
    [Abstract] [Full Text] [Related]

  • 24. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
    Shander A, Sazama K.
    Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
    [Abstract] [Full Text] [Related]

  • 25. [Secondary iron overload].
    Galacteros F.
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():44-8. PubMed ID: 9827215
    [No Abstract] [Full Text] [Related]

  • 26. Deferasirox: for iron overload: only a third-line option.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17929382
    [Abstract] [Full Text] [Related]

  • 27. Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy.
    Horodniceanu EG, Bal V, Dhatt H, Carter JA, Huang V, Lasch K.
    Health Qual Life Outcomes; 2017 Jun 23; 15(1):129. PubMed ID: 28645270
    [Abstract] [Full Text] [Related]

  • 28. Iron overload and chelation.
    Hershko C, Link G, Konijn AM, Ioav Cabantchik Z.
    Hematology; 2005 Jun 23; 10 Suppl 1():171-3. PubMed ID: 16188664
    [Abstract] [Full Text] [Related]

  • 29. [Iron overload diseases. Defects in the iron cycle].
    Ziegler R.
    Med Monatsschr Pharm; 2012 Sep 23; 35(9):332-5. PubMed ID: 23050350
    [No Abstract] [Full Text] [Related]

  • 30. Management of chronic iron overload.
    Baxter B.
    Paediatr Nurs; 2002 Sep 23; 14(7):14-6. PubMed ID: 12271869
    [No Abstract] [Full Text] [Related]

  • 31. The iron paradox: a case of acaeruloplasminaemia.
    Williamson J, Holt J.
    J R Coll Physicians Edinb; 2017 Jun 23; 47(2):148-150. PubMed ID: 28675187
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of at-home phlebotomy for iron overload: feasibility and satisfaction of patients and healthcare workers.
    Manea P, Loustaud-Ratti V, Mondary D, Arnold V, Ferley JP, Souris S, Fauchais AL, Liozon E, Vidal E.
    Gastroenterol Clin Biol; 2008 Feb 23; 32(2):172-9. PubMed ID: 18496893
    [Abstract] [Full Text] [Related]

  • 33. Modification of Patient Reported Outcomes Measures of Compliance, Gastrointestinal Symptoms, Palatability and Treatment Satisfaction for Patients Needing Iron Chelation therapy.
    Lasch K, Côté I, Roma T, Srivastava B, Horodniceanu EG, Dhatt H, Carter JA, Bal V.
    Value Health; 2014 Nov 23; 17(7):A574. PubMed ID: 27201926
    [No Abstract] [Full Text] [Related]

  • 34. New Observer-Reported Outcomes To Measure Treatment Satisfaction, Compliance, Palatability, and Gi Symptoms for Patients Needing Iron-Chelation Therapy.
    Lasch K, Horodniceanu EG, Carter JA, Dhatt H, Bal V, Côté I, Constantinovici N, Herranz RM, Malet I.
    Value Health; 2014 Nov 23; 17(7):A534-5. PubMed ID: 27201705
    [No Abstract] [Full Text] [Related]

  • 35. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Geneen LJ, Dorée C, Estcourt LJ.
    Cochrane Database Syst Rev; 2023 Mar 06; 3(3):CD012349. PubMed ID: 36877640
    [Abstract] [Full Text] [Related]

  • 36. Development of the Thalassaemia Adult Life Index (ThALI).
    Kantaris X, Shevlin M, Porter J, Myers L.
    Health Qual Life Outcomes; 2020 Jun 12; 18(1):180. PubMed ID: 32532297
    [Abstract] [Full Text] [Related]

  • 37. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 38. Is the Benefit-Risk Ratio for Patients with Transfusion-Dependent Thalassemia Treated by Unrelated Cord Blood Transplantation Favorable?
    Jaing TH.
    Int J Mol Sci; 2017 Nov 20; 18(11):. PubMed ID: 29156642
    [Abstract] [Full Text] [Related]

  • 39. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2016 Sep 20; 2016(9):. PubMed ID: 27713668
    [Abstract] [Full Text] [Related]

  • 40. Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.
    Senol SP, Tiftik EN, Unal S, Akdeniz A, Tasdelen B, Tunctan B.
    J Basic Clin Pharm; 2016 Mar 20; 7(2):49-59. PubMed ID: 27057126
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.